Boston Scien Cp Stock Price, News & Analysis

Boston Scientific reported Q4 2021 net sales of $3.127 billion, up 15.4% year-over-year, exceeding guidance. The net income was $80 million or $0.06 per share, down from $196 million or $0.14 per share a year ago. Adjusted EPS rose to $0.45 from $0.23. For FY 2021, total net sales reached $11.888 billion, up 19.9%, with a net income of $985 million ($0.69 per share). The company initiated the MODULAR ATP clinical trial and secured a 75% payment increase for Rezūm™ Water Vapor Therapy. Guidance for 2022 estimates sales growth of 6-8%.

Boston Scientific Corporation (NYSE: BSX) will present significant findings at the 25th North American Neuromodulation Society annual meeting in Orlando, Florida, from Jan. 13-15, 2022. Key highlights include a late-breaking presentation on the COMBO study, demonstrating the effectiveness of the WaveWriter™ Spinal Cord Stimulator System over two years. Additionally, updates on collaborations with IBM Research will showcase innovative AI-driven approaches to assess patient pain states.

Over 20 abstracts will be presented, emphasizing Boston Scientific's commitment to personalized chronic pain therapies.

Boston Scientific Corporation (NYSE: BSX) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 8:15 a.m. EST. CEO Mike Mahoney, CFO Dan Brennan, and VP Lauren Tengler will present and engage in Q&A. Additionally, a conference call to discuss the fourth quarter financial results for 2021 will be held on February 2, 2022, at 8:00 a.m. EST. The financial results will be announced prior to the call. Both events will be accessible via webcast at investors.bostonscientific.com.

Boston Scientific (BSX) has launched the MODULAR ATP clinical trial to assess the safety and efficacy of its mCRM™ Modular Therapy System, integrating the EMBLEM™ MRI Subcutaneous Implantable Defibrillator and the EMPOWER™ Modular Pacing System. This trial will enroll up to 300 patients across 50 centers in the U.S., Canada, and Europe to evaluate the system's complication-free rates, communication success, and pacing thresholds. The S-ICD is shown to prevent sudden cardiac death and has been successfully used in over 100,000 patients, enhancing patient care while minimizing invasive procedures.

Boston Scientific Corporation (NYSE: BSX) will participate in two key investor conferences. On November 15, 2021, CFO Dan Brennan and VP of Investor Relations Lauren Tengler will host a 30-minute Q&A at the virtual 2021 Stifel Healthcare Conference starting at 8:00 a.m. EST. Following this, on December 1, 2021, Dave Pierce, Brian Dunkin, and Lauren Tengler will conduct a 45-minute Q&A at the 2021 Evercore ISI HealthCONx Conference, also beginning at 8:00 a.m. EST.

Live webcasts and replays will be available at investors.bostonscientific.com.

Boston Scientific Corporation (NYSE: BSX) reported Q3 2021 net sales of $2.932 billion, a growth of 10.3% year-over-year. GAAP net income reached $405 million or $0.28 per share, compared to a loss of $169 million last year. Adjusted EPS improved to $0.41 from $0.37. Significant sales growth occurred across all segments, especially Cardiovascular, which rose 19.4%. Despite COVID-19 challenges impacting performance, the company anticipates full-year net sales growth of 19-20% and Q4 growth of 13-17%.

Boston Scientific Corporation (NYSE: BSX) announced positive results for the Eluvia Drug-Eluting Vascular Stent System during the VIVA meeting in Las Vegas on October 6, 2021. The EMINENT trial revealed a primary patency rate of 85.4% for the Eluvia stent, significantly higher than the 76.3% for bare metal stents (p=0.0077). The study enrolled 775 patients, marking it as the largest randomized trial for drug-eluting stents in peripheral artery disease (PAD). Clinical improvement without reintervention was 83.0% for the Eluvia stent compared to 76.6% for bare metal stents (p=0.0450).

Boston Scientific Corporation (NYSE: BSX) has announced a definitive agreement to acquire Baylis Medical Company for an upfront payment of $1.75 billion. This acquisition aims to enhance its electrophysiology and structural heart product lines by including advanced transseptal platforms that improve safety and efficiency for left heart procedures. Baylis is projected to generate $200 million in net sales in 2022, marking five years of double-digit growth. The deal is expected to close in Q1 2022, and is anticipated to be accretive to adjusted earnings per share.

Boston Scientific (NYSE: BSX) announced positive findings for its EkoSonic™ Endovascular System at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas. The KNOCOUT PE registry, which studied 489 patients across 83 centers, demonstrated the system's safety and efficacy in treating pulmonary embolism (PE) with a lower drug dose and shorter infusion duration. Notably, no intracerebral hemorrhagic events occurred, and the major bleeding rate was just 2.5%. The results also indicated a 23% reduction in heart strain post-procedure, underscoring the system's potential to enhance patient care.